Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30509740

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2019 Jan 12
First author
Cohen EEW

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2019 Jan 12;393(10167):108-109. doi: 10.1016/S0140-6736(18)32346-8.
    note
    Source null
    related pmid
    30509741
    relationship
    Comment in
  2. citation
    Lancet. 2019 Jan 12;393(10167):132. doi: 10.1016/S0140-6736(18)33261-6.
    note
    Source null
    related pmid
    31208766
    relationship
    Erratum in
  3. citation
    Strahlenther Onkol. 2019 Sep;195(9):851-854. doi: 10.1007/s00066-019-01485-y.
    note
    Source null
    related pmid
    31250051
    relationship
    Comment in
  4. citation
    Lancet. 2019 Oct 12;394(10206):1321-1322. doi: 10.1016/S0140-6736(19)31261-9.
    note
    Source null
    related pmid
    31609221
    relationship
    Comment in
  5. citation
    Lancet. 2019 Oct 12;394(10206):1322-1323. doi: 10.1016/S0140-6736(19)31260-7.
    note
    Source null
    related pmid
    31609222
    relationship
    Comment in

Authors and identifiers

  1. name
    Cohen EEW
    type
    Author
  2. name
    Soulières D
    type
    Author
  3. name
    Le Tourneau C
    type
    Author
  4. name
    Dinis J
    type
    Author
  5. name
    Licitra L
    type
    Author
  6. name
    Ahn MJ
    type
    Author
  7. name
    Soria A
    type
    Author
  8. name
    Machiels JP
    type
    Author
  9. name
    Mach N
    type
    Author
  10. name
    Mehra R
    type
    Author
  11. name
    Burtness B
    type
    Author
  12. name
    Zhang P
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Cohen EEW
    type
    Author
  2. name
    Soulières D
    type
    Author
  3. name
    Le Tourneau C
    type
    Author
  4. name
    Dinis J
    type
    Author
  5. name
    Licitra L
    type
    Author
  6. name
    Ahn MJ
    type
    Author
  7. name
    Soria A
    type
    Author
  8. name
    Machiels JP
    type
    Author
  9. name
    Mach N
    type
    Author
  10. name
    Mehra R
    type
    Author
  11. name
    Burtness B
    type
    Author
  12. name
    Zhang P
    type
    Author
bibliography ids
  1. nci-bib-78016cd9e31d77fe828f084f
book metadata
content sha256
8f62c3c2bab8db690915feaf2250cf777e70fef9f762a3f656e6f76f3501acfb
document type
citation
dois
  1. 10.1016/S0140-6736(18)31999-8
electronic publication date
display
2018 Nov 30
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:30509740
immutable id
pubmed:30509740@8f62c3c2bab8db690915feaf2250cf777e70fef9f762a3f656e6f76f3501acfb
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10167
name
Lancet (London, England)
nlm unique id
2985213R
pages
156-167
volume
393
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2019 Jan 12;393(10167):108-109. doi: 10.1016/S0140-6736(18)32346-8.
    note
    Source null
    related pmid
    30509741
    relationship
    Comment in
  2. citation
    Lancet. 2019 Jan 12;393(10167):132. doi: 10.1016/S0140-6736(18)33261-6.
    note
    Source null
    related pmid
    31208766
    relationship
    Erratum in
  3. citation
    Strahlenther Onkol. 2019 Sep;195(9):851-854. doi: 10.1007/s00066-019-01485-y.
    note
    Source null
    related pmid
    31250051
    relationship
    Comment in
  4. citation
    Lancet. 2019 Oct 12;394(10206):1321-1322. doi: 10.1016/S0140-6736(19)31261-9.
    note
    Source null
    related pmid
    31609221
    relationship
    Comment in
  5. citation
    Lancet. 2019 Oct 12;394(10206):1322-1323. doi: 10.1016/S0140-6736(19)31260-7.
    note
    Source null
    related pmid
    31609222
    relationship
    Comment in
outcomes validated
false
pmid
30509740
provenance
batch id
438b2803888025c6cf56
provider
NCBI PubMed ESummary
record sha256
64dab8d79ae130f7eb4f54533ce63c2410b3de075c5115632077563f122933b2
response sha256
0adf5ff07d3aa03a45feef5e4b7998e2ddea370eb9d1c6aa9134c5fd329767e6
retrieved at
2026-09-09T23:47:36.359220+00:00
publication date
display
2019 Jan 12
precision
day
year
2019
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30509740/
title
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

Preserved source evidence · Not medical advice